237 related articles for article (PubMed ID: 27779106)
1. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53 transgenic mouse model.
Deneka AY; Haber L; Kopp MC; Gaponova AV; Nikonova AS; Golemis EA
PLoS One; 2017; 12(4):e0176747. PubMed ID: 28453558
[TBL] [Abstract][Full Text] [Related]
3. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Proia DA; Smith DL; Zhang J; Jimenez JP; Sang J; Ogawa LS; Sequeira M; Acquaviva J; He S; Zhang C; Khazak V; Astsaturov I; Inoue T; Tatsuta N; Osman S; Bates RC; Chimmanamada D; Ying W
Mol Cancer Ther; 2015 Nov; 14(11):2422-32. PubMed ID: 26271675
[TBL] [Abstract][Full Text] [Related]
4. STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Heske CM; Mendoza A; Edessa LD; Baumgart JT; Lee S; Trepel J; Proia DA; Neckers L; Helman LJ
Oncotarget; 2016 Oct; 7(40):65540-65552. PubMed ID: 27608846
[TBL] [Abstract][Full Text] [Related]
5. A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.
Gaponova AV; Nikonova AS; Deneka A; Kopp MC; Kudinov AE; Skobeleva N; Khazak V; Ogawa LS; Cai KQ; Duncan KE; Duncan JS; Egleston BL; Proia DA; Boumber Y; Golemis EA
Clin Cancer Res; 2016 Oct; 22(20):5120-5129. PubMed ID: 27267850
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
Liao J; Chung YT; Yang AL; Zhang M; Li H; Zhang W; Yan L; Yang GY
Mol Carcinog; 2013 Sep; 52(9):739-50. PubMed ID: 22549877
[TBL] [Abstract][Full Text] [Related]
8. Mouse Models of Pancreatic Ductal Adenocarcinoma.
Ponz-Sarvise M; Tuveson DA; Yu KH
Hematol Oncol Clin North Am; 2015 Aug; 29(4):609-17. PubMed ID: 26226900
[TBL] [Abstract][Full Text] [Related]
9. Overall survival of pancreatic ductal adenocarcinoma is doubled by
Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
[No Abstract] [Full Text] [Related]
10. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
[TBL] [Abstract][Full Text] [Related]
11. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
12. Targeting mTOR dependency in pancreatic cancer.
Morran DC; Wu J; Jamieson NB; Mrowinska A; Kalna G; Karim SA; Au AY; Scarlett CJ; Chang DK; Pajak MZ; ; Oien KA; McKay CJ; Carter CR; Gillen G; Champion S; Pimlott SL; Anderson KI; Evans TR; Grimmond SM; Biankin AV; Sansom OJ; Morton JP
Gut; 2014 Sep; 63(9):1481-9. PubMed ID: 24717934
[TBL] [Abstract][Full Text] [Related]
13. Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.
Mace TA; Shakya R; Elnaggar O; Wilson K; Komar HM; Yang J; Pitarresi JR; Young GS; Ostrowski MC; Ludwig T; Bekaii-Saab T; Bloomston M; Lesinski GB
Oncotarget; 2015 Dec; 6(42):44509-22. PubMed ID: 26575024
[TBL] [Abstract][Full Text] [Related]
14. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
Wasko UN; Jiang J; Dalton TC; Curiel-Garcia A; Edwards AC; Wang Y; Lee B; Orlen M; Tian S; Stalnecker CA; Drizyte-Miller K; Menard M; Dilly J; Sastra SA; Palermo CF; Hasselluhn MC; Decker-Farrell AR; Chang S; Jiang L; Wei X; Yang YC; Helland C; Courtney H; Gindin Y; Muonio K; Zhao R; Kemp SB; Clendenin C; Sor R; Vostrejs WP; Hibshman PS; Amparo AM; Hennessey C; Rees MG; Ronan MM; Roth JA; Brodbeck J; Tomassoni L; Bakir B; Socci ND; Herring LE; Barker NK; Wang J; Cleary JM; Wolpin BM; Chabot JA; Kluger MD; Manji GA; Tsai KY; Sekulic M; Lagana SM; Califano A; Quintana E; Wang Z; Smith JAM; Holderfield M; Wildes D; Lowe SW; Badgley MA; Aguirre AJ; Vonderheide RH; Stanger BZ; Baslan T; Der CJ; Singh M; Olive KP
Nature; 2024 May; 629(8013):927-936. PubMed ID: 38588697
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Liao J; Hwang SH; Li H; Yang Y; Yang J; Wecksler AT; Liu JY; Hammock BD; Yang GY
Cancer Lett; 2016 Feb; 371(2):187-93. PubMed ID: 26683769
[TBL] [Abstract][Full Text] [Related]
16. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
17. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.
Byrne JD; Jajja MR; Schorzman AN; Keeler AW; Luft JC; Zamboni WC; DeSimone JM; Yeh JJ
Proc Natl Acad Sci U S A; 2016 Feb; 113(8):2200-5. PubMed ID: 26858448
[TBL] [Abstract][Full Text] [Related]
18. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
[TBL] [Abstract][Full Text] [Related]
19. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
20. The KRAS-PDEδ interaction is a therapeutic target.
Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
